share_log
Benzinga ·  Aug 22 07:34
Palatin Technologies Has Started Patient Dosing In Phase 2 Study Of Bremelanotide Co-administered With Tirzepatide For Obesity, Complete Enrollment Is Currently Expected In 3Q 2024, With Topline Data Expected In Q1 Calendar Year 2025
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment